Recently, indoleamine 2,3‐dioxygenase (IDO) inhibitors have also been trialled, without success, with neoadjuvant immunotherapy in untreated LA HNSCC to improve pathological response.43 Here, IDO1 is linked to head and neck squamous cell carcinoma.